The 73 references in paper A. Kadushkin G., A. Taganovich D., N. Taganovich D., А. Кадушкин Г., А. Таганович Д., Н. Таганович Д. (2014) “Целесообразность и перспективы применения антицитокиновой и иммунокорригирующей терапии у пациентов с хронической обструктивной болезнью легких // Reasonability and perspectives of anti-cytokine and immune correcting therapy in patients with chronic obstructive pulmonary disease” / spz:neicon:pulmonology:y:2013:i:5:p:61-69

1
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Global Initiative for Chronic Obstructive Lung Disease (GOLD)
(check this in PDF content)
2
11. http://www.goldcopd.org 2.Gershon A.S., Warner L., Cascagnette P. et al. Lifetime risk of developing chronic obstructive pulmonary disease: a longitudinal population study. Lancet 2011; 378 (9795): 991–996.
(check this in PDF content)
3
Архипов В.В.Хроническая обструктивная болезнь легких: фармакоэкономические аспекты. Пульмонология 2010; 4: 99–104.
(check this in PDF content)
4
Кадушкин А.Г., Таганович А.Д., Лаптева И.М.Эпидемиологические особенности хронической обструктивной болезни легких у городских жителей Республики Беларусь. Здравоохранение 2013; 7: 21–25.
(check this in PDF content)
5
Tee A.A new gold standard – pharmacological interventions of COPD. Singapore Fam. Physician 2013; 39 (2): 15–18.
(check this in PDF content)
6
Calverley P.M., Anderson J.A., Celli B. et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007; 356 (8): 775–789.
(check this in PDF content)
7
Drummond M.B., Dasenbrook E.C., Pitz M.W. et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. J.A.M.A. 2008; 300 (20): 2407–2416.
(check this in PDF content)
8
Nannini L.J., Cates C.J., Lasserson T.J. et al.Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2007; 4: CD003794.
(check this in PDF content)
9
Valk P., Monninkhof E., van der Palen J. et al.Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am. J. Respir. Crit. Care Med. 2002; 166 (10): 1358–1363.
(check this in PDF content)
10
Crim C., Calverley P.M., Anderson J.A. et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur. Respir. J. 2009; 34 (3): 641–647.
(check this in PDF content)
11
Barnes P.J. Development of new drugs for COPD. Curr. Med. Chem. 2013; 20 (12): 1531–1540.
(check this in PDF content)
12
Kodgule R., Vaidya A., Salvi S. Newer therapies for chronic obstructive pulmonary disease. J. Assoc. Physicians India 2012; 60 (Suppl.): 8–13.
(check this in PDF content)
13
Boer W.I., Yao H., Rahman I. Future therapeutic treatment of COPD: struggle between oxidants and cytokines. Int. J. Chron. Obstruct. Pulm. Dis. 2007; 2 (3): 205–228.
(check this in PDF content)
14
Plataki M., Tzortzaki E., Rytila P. et al.Apoptotic mechanisms in the pathogenesis of COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2006; 1 (2): 161–171.
(check this in PDF content)
15
Кадушкин А.Г., Таганович А.Д. Молекулярно-клеточные механизмы развития хронической обструктивной болезни легких. Воен. мед. журн. 2012; 1: 132–138.
(check this in PDF content)
16
Barnes P.J. The cytokine network in chronic obstructive pulmonary disease. Am. J. Respir. Cell Mol. Biol. 2009; 41 (6): 631–638.
(check this in PDF content)
17
ClinicalTrials.gov.A randomized, double-blind, placebo controlled, exploratory study to assess the safety and efficacy of multiple doses of ACZ885 in chronic obstructive pulmonary disease (COPD) patients. 2011. Accessed 28/08/13 at:http:// clinicaltrials.gov/ct2/show/study/NCT00581945
(check this in PDF content)
18
Murphy P.M. Neutrophil receptors for interleukin-8 and related CXC chemokines. Semin. Hematol. 1997; 34 (4): 311–318.
(check this in PDF content)
19
Keatings V.M., Collins P.D., Scott D.M. et al. Differences in interleukin-8 and tumor necrosis factor-αin induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am. J. Respir. Crit. Care Med. 1996; 153 (2): 530–534.
(check this in PDF content)
20
Nadel J.A.Role of neutrophil elastase in hypersecretion during COPD exacerbations, and proposed therapies. Chest 2000; 117 (5, Suppl. 2): 386s–389s.
(check this in PDF content)
21
Beeh K.M., Kornmann O., Buhl R. et alNeutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4. Chest 2003; 123 (4): 1240–1247.
(check this in PDF content)
22
Mahler D.A., Huang S., Tabrizi M. et al.Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. Chest 2004; 126 (3): 926–934.
(check this in PDF content)
23
O'Connor B.J., Leaker B.R., Barnes P.J. et al. Inhibition of LPS-induced neutrophilic inflammation in healthy volunteers [abstract]. Eur. Respir. J. 2007; 30 (Suppl. 1): 209s.
(check this in PDF content)
24
Kirsten A.M., Förster K., Radeczky E. et al.The safety and tolerability of twice-daily oral doses of AZD5069, a novel CXCR2 antagonist, in patients with moderate-to-severe COPD. Eur. Respir. J. 2012; 40 (Suppl. 56): 546s.
(check this in PDF content)
25
Kanniess F., Khalilieh S., Ludwig&Sengpiel A. et al. SCH 527123, a CXCR2 antagonist, inhibits ozone-induced airway neutrophilia in healthy subjects. Eur. Respir. J. 2007; 30 (Suppl. 1): 209s.
(check this in PDF content)
26
Lazaar A.L., Sweeney L.E., MacDonald A.J. et al.SB656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans. Br. J. Clin. Pharmacol. 2011; 72 (2): 282–293.
(check this in PDF content)
27
Chapman R.W., Phillips J.E., Hipkin R.W. et al. CXCR2 antagonists for the treatment of pulmonary disease. Pharmacol. Ther. 2009; 121 (1): 55–68.
(check this in PDF content)
28
Chung K.F.Cytokines in chronic obstructive pulmonary disease. Eur. Respir. J. 2001; 18 (34): 50s–59s.
(check this in PDF content)
29
Chen Y.F., Jobanputra P., Barton P. et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Hlth Technol. Assess. 2006; 10 (42): III–IV, XI–XIII, 1–229.
(check this in PDF content)
30
Guo Y., Lu N., Bai A. Clinical use and mechanisms of infliximab treatment on inflammatory bowel disease: A recent update. Biomed. Res. Int. 2013; 2013: 581631.
(check this in PDF content)
31
Matera M.G., Calceta L., Cazzola M. TNF-αinhibitors in asthma and COPD: we must not throw the baby out with the bath water. Pulm. Pharmacol. Ther. 2010; 23 (2): 121–128.
(check this in PDF content)
32
Rennard S.I., Fogarty C., Kelsen S. et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2007; 175 (9): 926–934.
(check this in PDF content)
33
Moriconi F., Malik I.A., Amanzada A. et al.The anti-TNF-α antibody infliximab indirectly regulates PECAM-1 gene expression in two models of in vitro blood cell activation. Lab. Invest. 2012; 92 (2): 166–177.
(check this in PDF content)
34
Dickens J.A., Miller B.E., Edwards L.D. et al. COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. Respir. Res. 2011; 12:146.
(check this in PDF content)
35
Kim S.Y., Solomon D.H. Tumor necrosis factor blockade and the risk of viral infection. Nature Rev. Rheumatol. 2010; 6 (3): 165–174.
(check this in PDF content)
36
Boer W.I., van Schadewijk A., Sont J.K. et al. Transforming growth factor β1and recruitment of macrophages and mast cells in airways in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 158 (6): 1951–1957.
(check this in PDF content)
37
Wang Q., Usinger W., Nichols B. et al. Cooperative interaction of CTGF and TGF-βin animal models of fibrotic disease. Fibrogenes. Tissue Repair. 2011; 4 (1): 4.
(check this in PDF content)
38
Barnes P.J. New approaches to COPD. Eur. Respir. Rev. 2005; 14 (94): 2–11.
(check this in PDF content)
39
Mak J.C., Rousell J., Haddad E.B. et al.Transforming growth factor-β1inhibits β2-adrenoceptor gene transcription. Naunyn Schmiedeberg,s Arch. Pharmacol. 2000; 362 (6): 520–525.
(check this in PDF content)
40
Ishikawa T., Kume H., Kondo M. et al. Inhibitory effects of interferon-gamma on the heterologous desensitization of betaadrenoceptors by transforming growth factor-β1in tracheal smooth muscle. Clin. Exp. Allergy 2003; 33 (6): 808–815.
(check this in PDF content)
41
Takizawa H., Tanaka M., Takami K. et al.Increased expression of transforming growth factor-β1in small airway epithelium from tobacco smokers and patients with chronic obstructive pulmonary disease (COPD). Am. J. Respir. Crit. Care Med. 2001; 163 (6): 1476–1483.
(check this in PDF content)
42
Mak J.C., Chan&Yeung M.M., Ho S.P. et al. Elevated plasma TGF-β1levels in patients with chronic obstructive pulmonary disease. Respir. Med. 2009; 103 (7): 1083–1089.
(check this in PDF content)
43
Leung S.Y., Niimi A., Noble A. et al.Effect of transforming growth factor-beta receptor I kinase inhibitor 2,4-disubstituted pteridine (SD-208) in chronic allergic airway inflammation and remodeling. J. Pharmacol. Exp. Ther. 2006; 319 (2): 586–594.
(check this in PDF content)
44
ClinicalTrials.gov.Open label trial of anti-TGF-beta mab, fresolimumab, in systemic sclerosis – a phase one biomarker trial. 2012. Accessed 28/08/13 at: http://clinicaltrials.gov/ ct2/show/NCT01284322
(check this in PDF content)
45
ClinicalTrials.gov.A Phase 2, multicenter, double-blind, parallel dosing, randomized study of fresolimumab or placebo in patients with steroid-resistant primary focal segmental glomerulosclerosis. 2013. Accessed 28/08/13 at: http://clin& icaltrials.gov/ct2/show/NCT01665391
(check this in PDF content)
46
ClinicalTrials.gov.Fresolimumab and radiotherapy in metastatic breast cancer. 2013. Accessed 28/08/13 at: http://clin& icaltrials.gov/ct2/show/NCT01401062
(check this in PDF content)
47
Privratsky J.R., Newman D.K., Newman P.J. PECAM-1: Conflicts of Interest in Inflammation. Life Sci. 2010; 87 (3–4): 69–82. Кадушкин А.Г. и др.Целесообразность применения антицитокиновой и иммунокорригирующей терапии
(check this in PDF content)
48
Blidberg K., Palmberg L., James A. et al.Adhesion molecules in subjects with COPD and healthy non-smokers: a cross sectional parallel group study. Respir. Res. 2013; 14: 47.
(check this in PDF content)
49
Takahashi T., Kobayashi S., Fujino N. et al. Increased circulating endothelial microparticles in COPD patients: a potential biomarker for COPD exacerbation susceptibility. Thorax 2012; 67 (12): 1067–1074.
(check this in PDF content)
50
Dasgupta B., Chew T., deRoche A. et al. Blocking platelet / endothelial cell adhesion molecule 1 (PECAM) inhibits disease progression and prevents joint erosion in established collagen antibody induced arthritis. Exp. Mol. Pathol. 2010; 88 (1): 210–215.
(check this in PDF content)
51
Gumina R.J., el Schultz J., Yao Z. et al. Antibody to platelet/endothelial cell adhesion molecule-1 reduces myocardial infarct size in a rat model of ischemia-reperfusion injury. Circulation 1996; 94 (12): 3327–3333.
(check this in PDF content)
52
Кадушкин А.Г., Таганович А.Д. Роль хемокинов в патогенезе хронической обструктивной болезни легких. Мед. журн. 2012; 2: 139–144.
(check this in PDF content)
53
Кадушкин А.Г., Шман Т.В., Белевцев М.В. и др.Популяционная перестройка Т-лимфоцитов, содержащих хемокиновые рецепторы, у пациентов с хронической обструктивной болезнью легких. Пульмонология 2013; 2: 41–45.
(check this in PDF content)
54
O'Boyle G., Fox C.R., Walden H.R. et al. Chemokine receptor CXCR3 agonist prevents human T-cell migration in a humanized model of arthritic inflammation. Proc. Natl Acad. Sci. USA 2012; 109 (12): 4598–4603.
(check this in PDF content)
55
Vinet J., van Zwam M., Dijkstra I.M. et al.Inhibition of CXCR3-mediated chemotaxis by the human chemokine receptor-like protein CCX-CKR. Br. J. Pharmacol. 2013; 168 (6): 1375–1387.
(check this in PDF content)
56
Yellin M., Paliienko I., Balanescu A. et al. A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human antiCXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis. Arthr. and Rheum. 2012; 64 (6): 1730–1739.
(check this in PDF content)
57
Romero&Sanchez M.C., Machmach K., Gonzalez&Serna A. et al. Effect of maraviroc on HIV disease progression-related biomarkers. Antimicrob. Agents Chemother. 2012; 56 (11):
(check this in PDF content)
58
8–5864. 58.Gilliam B.L., Riedel D.J., Redfield R.R. Clinical use of CCR5 inhibitors in HIV and beyond. J. Transl. Med. 2011; 9 (Suppl. 1): 9s.
(check this in PDF content)
59
Kuijk A.W., Vergunst C.E., Gerlag D.M. et al.CCR5 blockade in rheumatoid arthritis: a randomised, doubleblind, placebo-controlled clinical trial. Ann. Rheum. Dis. 2010; 69 (11): 2013–2016.
(check this in PDF content)
60
Groot M., Teunissen M.B., Ortonne J.P. et al.Expression of the chemokine receptor CCR5 in psoriasis and results of a randomized placebo controlled trial with a CCR5 inhibitor. Arch. Dermatol. Res. 2007; 299 (7): 305–313.
(check this in PDF content)
61
Liu S.F., Chin C.H., Wang C.C. et al. Correlation between serum biomarkers and BODE index in patients with stable COPD. Respirology 2009; 14 (7): 999–1004.
(check this in PDF content)
62
Traves S.L., Culpitt S.V., Russell R.E. et al.Increased levels of the chemokines GROαand MCP-1 in sputum samples from patients with COPD. Thorax 2002; 57 (7): 590–595.
(check this in PDF content)
63
Boer W.I., Sont J.K., van Schadewijk A. et al. Monocyte chemoattractant protein 1, interleukin 8, and chronic airways inflammation in COPD. J. Pathol. 2000; 190 (5): 619–626.
(check this in PDF content)
64
Xia M., Sui Z.Recent developments in CCR2 antagonists. Expert Opin. Ther. Path. 2009; 19 (3): 295–303.
(check this in PDF content)
65
Ralainirina N., Poli A., Michel T.Control of NK cell functions by CD4+CD25+regulatory T cells. J. Leukoc. Biol. 2007; 81 (1): 144–153.
(check this in PDF content)
66
Кадушкин А.Г., Шман Т.В., Новиков В.П. и др.Особенности количественного изменения регуляторных T-лимфоцитов у пациентов с хронической обструктивной болезнью легких. Пульмонология 2013; 3: 25–30.
(check this in PDF content)
67
Miyara M., Yoshioka Y., Kitoh A. et al.Functional delineation and differentiation dynamics of human CD4+T cells expressing the FoxP3 transcription factor. Immunity 2009; 30 (6): 899–911.
(check this in PDF content)
68
Hou J., Sun Y., Hao Y. et al. Imbalance between subpopulations of regulatory T cells in COPD. Thorax 2013. doi: 10.1136/thoraxjnl-2012-201956.
(check this in PDF content)
69
Abdullah M., Chai P.S., Loh C.Y. et al.Carica papaya increases regulatory T cells and reduces IFN-γ+CD4+ T-cells in healthy human subjects. Mol. Nutr. Food Res. 2011; 55 (5): 803–806.
(check this in PDF content)
70
Wong C.P., Nguyen L.P., Noh S.K. et al.Induction of regulatory T cells by green tea polyphenol EGCG. Immunol. Lett. 2011; 139 (1–2): 7–13.
(check this in PDF content)
71
Lane N., Robins R.A., Corne J. Regulation in chronic obstructive pulmonary disease: the role of regulatory T-cells and Th17 cells. Clin. Sci. 2010; 119 (2): 75–86.
(check this in PDF content)
72
Louten J., Boniface K., de Waal Malefyt R.Development and function of TH17 cells in health and disease. J. Allergy Clin. Immunol. 2009; 123 (5): 1004–1011.
(check this in PDF content)
73
Jones C.E., Chan K. Interleukin-17 stimulates the expression of interleukin-8, growth-related oncogene-alpha, and granulocyte- colony-stimulating factor by human airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 2002; 26 (6):
(check this in PDF content)